Journal of Clinical Lipidology
-
Publication Venue For
-
Uptake of non-statin lipid-lowering therapies for secondary prevention in community practice.
2023
-
Assessment and management of statin-associated muscle symptoms (SAMS): A clinical perspective from the National Lipid Association..
17:19-39.
2023
-
From the editor: Intensive exercise and insights from women..
17:1-2.
2023
-
From the editor: The role of generalists in clinical lipidology..
17:197.
2023
-
Is hypertriglyceridemia a reliable indicator of cholesterol-depleted apoB particles?
2023
-
JCL Roundtable: From Gen Med to Clinical Lipidology..
17:199-207.
2023
-
JCL Roundtable: Lipidology and Women's Health..
17:4-11.
2023
-
From the editor: Eglerio! The Ringbearers, praise them!.
16:247-248.
2022
-
From the editor: A compendium of lipidology progress..
16:761-762.
2022
-
From the editor: A time of renewal for clinical lipidology..
16:359.
2022
-
From the editor: Heroes in a historic time..
16:1.
2022
-
From the editor: Hope and strength in community..
16:113.
2022
-
From the editor: Lipidology resurgent as the pandemic wanes..
16:545.
2022
-
JCL Roundtable. Obesity, Diabetes, and Liver Disease in Relation to Cardiovascular Risk..
16:115-127.
2022
-
JCL Roundtable. The lipidology team..
16:3-12.
2022
-
Extreme elevations of low-density lipoprotein cholesterol with very low carbohydrate, high fat diets..
15:525-526.
2021
-
Clinical reasoning and prevention of cardiovascular disease..
15:394-398.
2021
-
From the editor: Competition and community..
15:243.
2021
-
From the editor: Coyotes on the lawn..
15:619.
2021
-
From the editor: From a hell of a year to "Hello Telemedicine"..
15:383-384.
2021
-
From the editor: Prevention then and now..
15:527.
2021
-
From the editor: Rounding the corner..
15:1.
2021
-
From the editor: Trust and the value paradox in science..
15:761-762.
2021
-
JCL Roundtable. Making prevention a priority..
15:530-537.
2021
-
JCL Roundtable: Global Think Tank on Lipoprotein(a)..
15:387-393.
2021
-
JCL roundtable: Lipids and inflammation in atherosclerosis..
15:3-17.
2021
-
Efficacy and safety of alirocumab in statin-intolerant patients over 3 years: open-label treatment period of the ODYSSEY ALTERNATIVE trial..
14:88-97.e2.
2020
-
From the editor: Confronting a pandemic or two..
14:159.
2020
-
From the editor: Connectedness and lipidology..
14:611.
2020
-
From the editor: Moral choices and human health..
14:743-744.
2020
-
From the editor: Never send to know for whom the bell tolls..
14:381-382.
2020
-
From the editor: Plagues and the ancient legacy of Epimenides..
14:271-272.
2020
-
From the editor: The "roaring Twenties" revisited?.
14:1-2.
2020
-
JCL roundtable: Healthy ethnic diets..
14:274-281.
2020
-
JCL roundtable: Low-carbohydrate diets..
14:384-395.
2020
-
JCL roundtable: Omega-3 fatty acids and cardiovascular outcomes..
14:4-15.
2020
-
JCL roundtable: South Asian atherosclerotic risk..
14:161-169.
2020
-
The association between triglycerides and incident cardiovascular disease: What is "optimal"?.
14:438-447.e3.
2020
-
From the editor: Atherosclerosis in different flavors..
13:341-342.
2019
-
From the editor: Considering less carbohydrate..
13:673-674.
2019
-
From the editor: Homeward bound?.
13:509.
2019
-
From the editor: Humans are animals and therefore make saturated fat..
13:1-2.
2019
-
From the editor: Margaritaville blues and Philadelphia news..
13:857-858.
2019
-
From the editor: New ACC/AHA/Multisociety Cholesterol Guidelines..
13:219-220.
2019
-
Impact on cardiometabolic risk of a weight loss intervention with higher protein from lean red meat: Combined results of 2 randomized controlled trials in obese middle-aged and older adults..
13:920-931.
2019
-
Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results from an open-label extension of the ODYSSEY LONG TERM trial..
13:138-147.
2019
-
JCL Roundtable: Lipid clinic operations..
13:511-521.
2019
-
JCL roundtable. The 2018 AHA/ACC/Multisociety Cholesterol Guidelines: Process and product..
13:345-355.
2019
-
JCL roundtable: Coronary artery calcium scoring and other vascular imaging for risk assessment..
13:4-14.
2019
-
JCL roundtable: Lipid treatment targets..
13:223-230.
2019
-
JCL roundtable: Pediatric lipidology..
13:676-688.
2019
-
Alirocumab dosing patterns during 40 months of open-label treatment in patients with heterozygous familial hypercholesterolemia..
12:1463-1470.
2018
-
From the editor: A run of success in treating atherosclerotic vascular disease..
12:1-2.
2018
-
From the editor: Lessons from the East..
12:1331-1332.
2018
-
From the editor: O Canada! A tariff-free zone for scientific exchange..
12:831-832.
2018
-
From the editor: Weighing the advantages of lipid conference and journal..
12:251-252.
2018
-
From the editor: What is the bottom line for clinical lipidology research?.
12:1083-1084.
2018
-
JCL roundtable-Lipoprotein(a): The emerging risk factor..
12:1335-1345.
2018
-
JCL roundtable: High-density lipoprotein function and reverse cholesterol transport..
12:1086-1094.
2018
-
Old news and a new order..
12:571.
2018
-
PCSK9 inhibitors for prevention of atherosclerotic cardiovascular disease..
12:835-843.
2018
-
Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial..
12:348-355.e2.
2018
-
Roundtable discussion: Dietary fats in prevention of atherosclerotic cardiovascular disease..
12:574-582.
2018
-
From the Editor..
11:1109.
2017
-
From the Editor..
11:1297.
2017
-
Marine omega-3 fatty acids and cardiac death..
11:1124-1125.
2017
-
Niacin and heart disease prevention: Engraving its tombstone is a mistake..
11:1309-1317.
2017
-
Lipids and bariatric procedures part 1 of 2: Scientific statement from the National Lipid Association, American Society for Metabolic and Bariatric Surgery, and Obesity Medicine Association: EXECUTIVE SUMMARY..
10:15-32.
2016
-
Lipids and bariatric procedures part 1 of 2: Scientific statement from the National Lipid Association, American Society for Metabolic and Bariatric Surgery, and Obesity Medicine Association: FULL REPORT..
10:33-57.
2016
-
Statin intolerance in a referral lipid clinic..
10:870-879.e3.
2016
-
Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia..
10:905-914.
2016
-
US physician practices for diagnosing familial hypercholesterolemia: data from the CASCADE-FH registry..
10:1223-1229.
2016
-
Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial..
9:758-769.
2015
-
An assessment by the Statin Cognitive Safety Task Force: 2014 update..
8:S5-16.
2014
-
An assessment by the Statin Intolerance Panel: 2014 update..
8:S72-S81.
2014
-
Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial..
8:554-561.
2014
-
Erratum: Clinical management of individuals with obesity (Journal of Clinical Lipidology (2014) 8:3 (237-248)).
8:460.
2014
-
Adverse reactions of Achilles tendon xanthomas in three hypercholesterolemic patients after treatment intensification with niacin and bile acid sequestrants..
7:178-181.
2013
-
Inherited lipemic splenomegaly and the spectrum of apolipoprotein E p.Leu167del mutation phenotypic variation..
7:566-572.
2013
-
Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting..
7:102-108.
2013
-
Elevation of fasting morning glucose relative to hemoglobin A1c in normoglycemic patients treated with niacin and with statins..
6:168-173.
2012
-
Low glycemic diet for weight loss in hypertriglyceridemic patients attending a lipid clinic..
4:508-514.
2010
-
The use of lipid-lowering drugs in children..
4:449-461.
2010
-
Flushing and other dermatologic adverse events associated with extended-release niacin therapy..
3:101-108.
2009
-
The use of niacin..
3:65-69.
2009
-
Optimal management of lipids in diabetes and metabolic syndrome..
2:335-342.
2008
-
Effect of ezetimibe/simvastatin vs atorvastatin on lowering levels of LDL-C and non-HDL-C, ApoB, and hs-CRP in patients with type 2 diabetes..
2:25-35.
2008
-
Lipoprotein and apolipoprotein ratios in the VYTAL trial of ezetimibe/simvastatin compared with atorvastatin in type 2 diabetes..
2:19-24.
2008
-
LDL Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study - Implications for LDL Management..
1:583-592.
2007